NCT02697838

Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric cancer which paclitaxel-resistant.

Detailed description

This trial investigated the efficacy and safety of apatinib plus paclitaxel, as a treatment option for patients with advanced gastric cancer which paclitaxel-resistant.

Conditions

• Malignant Neoplasm of Stomach Stage II

Interventions

Type	Name	Description
DRUG	Apatinib	Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
DRUG	Paclitaxel-based chemotherapeutic regimens	Paclitaxel-based chemotherapeutic regimens including: 1. The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. 2. The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. 3. Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days 4. other paclitaxel-based regimens

Timeline

• Start date: 2016-08-01
• Primary completion: 2018-03-31
• Completion: 2018-10-31
• First posted: 2016-03-03
• Last updated: 2018-10-17

Locations

1 site across 1 country: China